Commonwealth Retirement Investments LLC Reduces Holdings in Bristol Myers Squibb Company $BMY

Commonwealth Retirement Investments LLC decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 75.3% during the second quarter, HoldingsChannel reports. The fund owned 17,829 shares of the biopharmaceutical company’s stock after selling 54,306 shares during the quarter. Commonwealth Retirement Investments LLC’s holdings in Bristol Myers Squibb were worth $1,027,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank bought a new position in Bristol Myers Squibb during the 4th quarter valued at about $1,947,272,000. AQR Capital Management LLC lifted its stake in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after purchasing an additional 16,332,924 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Bristol Myers Squibb by 47.0% in the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after purchasing an additional 7,837,485 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares during the period. Finally, Man Group plc grew its stake in shares of Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after buying an additional 5,503,391 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $63.86 on Friday. The company has a 50 day moving average price of $59.56 and a 200-day moving average price of $58.97. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10. The company has a market capitalization of $130.45 billion, a PE ratio of 14.07, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.96 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Wall Street Analysts Forecast Growth

BMY has been the topic of several recent analyst reports. Royal Bank Of Canada increased their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Cantor Fitzgerald restated a “neutral” rating and set a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Sanford C. Bernstein upgraded Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, July 30th. Finally, Truist Financial reissued a “buy” rating and set a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.